NYSE · Biotech stocks database
DNA (Ginkgo Bioworks Holdings Inc.) stock: $11.97, $776.0M market cap, $302.2M cash, $473.8M EV, $894.9M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Ginkgo Bioworks sells biological R&D services to government and commercial customers in two business segments: cell engineering, where it provides tools and biological R&D services across industries including medicine, agriculture and industrial biotechnology, and biosecurity services. The company does not make end products; instead it offers R&D services on its cell engineering platform, built around laboratory automation and reusable data assets, designed to give customers better probability of success, speed, or cost than traditional in-house lab work.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $302.2M |
|---|---|
| Debt | $0.0M |
| Net cash | $302.2M |
| Enterprise value | $473.8M |
| Basic shares | 64.3M shares |
| Fully diluted shares | 74.8M shares |
| Fully diluted market cap | $894.9M |
| Cash per share | $4.70 |
| Quarterly burn | $44.3M |
| Cash runway | 6.8 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-11.
Cap table as of 2026-07-31.
Loading DNA daily closes…